Neostigmine

Revision as of 20:58, 8 February 2017 by Mholtz (talk | contribs) (Text replacement - "-->" to "→")

Administration

  • Type: Cholinesterase inhibitor
  • Dosage Forms:
  • Routes of Administration: IV, oral (not FDA-approved)
  • Common Trade Names:

Adult Dosing

Pediatric Dosing

  • Safety/efficacy not well-established in peds, but generally same weight-based dosing as adults

Special Populations

Contraindications

  • Allergy to class/drug
  • Mechanical bowel or urinary tract obstruction
  • Peritonitis

Adverse Reactions

Serious

  • Bradyarrythmia, Atrioventricular block
  • Seizure, loss of conciousness

Common

  • Hypotension
  • Nausea, vomiting

Pharmacology

  • Half-life: 40-75 min
  • Metabolism: Hepatic (extensive)
  • Excretion: Renal

Mechanism of Action

  • Competitive cholinesterase inhibitor→ less breakdown of acetylcholine→ more acetylcholine in synapses

Comments

See Also

References